Lessons from COVID-19 clinical trials and the concept of national clinical trials network_Chinese Journal of Evidence-Based Medicine

Authors：

YAO Chen ^1,2 ,  ZHAO Wenle ³

1. First Hospital, Peking University, Beijing 100034, P.R.China;
2. Clinical Research Institute, Peking University, Beijing 100191, P.R.China;
3. Department of Public Health Sciences, Medical University of South Carolina, Charleston 29425, SC, USA;

Corresponding author：

ZHAO Wenle, Email: zhaow@musc.edu

Keywords：

Coronavirus disease (COVID-19); Clinical trial; National clinical trials network

DOI：

10.7507/1672-2531.202003069

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Since the outbreak of the coronavirus disease (COVID-19), more than 200 interventional clinical trials have been registered in Chinese Clinical Trial Registry (www.chictr.org.cn) and the US Clinical Trials Registry (www.clinicaltrials.gov), testing or going to test treatments of COVID-19 in China from January 23^rd, 2020 to March 5^th, 2020. This situation has drawn attentions from various sectors of society. This article summarizes the basic design features of 249 registered COVID-19 clinical trials in China, compares them with National Clinical Trials Network practices in the USA, and describes a concept of national clinical trials network as a strategy to enhance quality and efficiency of clinical research in cases like COVID-19 outbreak as well as other disease fields.

Citation： YAO Chen, ZHAO Wenle. Lessons from COVID-19 clinical trials and the concept of national clinical trials network. Chinese Journal of Evidence-Based Medicine, 2020, 20(5): 497-503. doi: 10.7507/1672-2531.202003069 Copy

Next Article
Development of rapid advice guidelines in public health emergency

1.	World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Available from: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).
2.	World Health Organization. Coronavirus disease (COVID-19) technical guidance: early investigations protocols. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus- 2019/technical-guidance/early-investigations.
3.	上海国际问题研究院. 中国抗击新型冠状病毒: 进展与前景. Available from: http://www.siis.org.cn/Content/Info/4U9RHLFMTUQR.
4.	Code of Federal Regulations. Title 21: food and drugs. 2017. Available from: https://www.govinfo.gov/content/pkg/CFR-2017-title21-vol5/pdf/CFR-2017-title21-vol5.pdf.
5.	中国临床试验注册中心. 新型冠状病毒肺炎临床研究索引. Available from: http://www.chictr.org.cn.
6.	U.S. National Library of Medicine. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov.
7.	金雪娟, 王吉耀. 冠状病毒感染疾病-19 临床研究的思考和建议. 中华消化杂志, 2020. DOI: 10.3760/cma.j.issn.0254-1432.2020.0004.
8.	陈峰, 姜庆五, 郝元涛, 等. 关于科学, 规范, 有序地开展新型冠状病毒肺炎相关临床试验的建议. 中华流行病学杂志, 2020, 41(3): 301-302.
9.	元唯安, 胡义扬, 唐健元, 等. 当下新型冠状病毒肺炎中药临床研究的若干思考. 上海中医药杂志, 2020. DOI: 10.16305/j.1007-1334.2020.04.099.
10.	罗艺, 蒋志伟. 新冠肺炎应急临床试验设计中的统计学考虑. 中国临床药理学与治疗学, 2020, 25(2): 121-125.
11.	曾繁典. 新型冠状病毒肺炎疫情下相关临床试验的伦理考量. 医药导报, 2020. Available from: http://kns.cnki.net/kcms/detail/42.1293.R.20200227.1803.003.html.
12.	陈永, 杨泽民, 陈吉生, 等. 新型冠状病毒肺炎药物临床试验现状及研究进展. 今日药学, 2020. Available from: http://kns.cnki.net/kcms/detail/44.1650.R.20200226.0753.002.html.
13.	宋杲, 成梦群, 魏贤文. 新型冠状病毒临床试验注册特点分析: 基于美国ClinicalTrials.gov和中国临床研究注册中心数据库. 中国人兽共患病学报, 2020. Available from: http://kns.cnki.net/kcms/detail/35.1284.R.20200224.1525.002.html.
14.	邓宏勇, 赵咏芳, 许吉, 等. 中医药防治新型冠状病毒肺炎临床循证研究注册动态分析报告. 上海中医药杂志, 2020, 54(3): 14-15.
15.	张晓雨, 赵晨, 孙杨, 等. 推动建立临床试验协作与共享机制: 疫情蔓延期的战略思考. 中医杂志, 2020. Available from: http://kns.cnki.net/kcms/detail/11.2166.r.20200219.1436.002.html.
16.	World Medical Association. Declaration of Helsinki - Ethical principles for medical research involving human subjects. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/..
17.	Freedman B. Equipoise and the ethics of clinical research. N Engl J Med, 1987, 317(3): 141-145.
18.	国务院应对新冠肺炎疫情联防联控机制科研攻关组. 关于规范医疗机构开展新型冠状病毒肺炎药物治疗临床研究的通知. Available from: http://www.most.gov.cn/tztg/202002/t20200225_151897.htm.
19.	中华人民共和国国家卫生健康委员会规划发展与信息化司. 2017 年我国卫生健康事业发展统计公报. Available from: http://www.nhc.gov.cn/guihuaxxs/s10743/201806/44e3cdfe11fa4c7f928c879d435b6a18.shtml.
20.	Moore TJ, Zhang H, Anderson G, et al. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med, 2018, 178(11): 1451-1457.
21.	Clinical Trials Arena. Clinical trial delays: America’s patient recruitment dilemma. Available from: https://www.clinicaltrialsarena.com/analysis/featureclinical-trial-patient-recruitment/.
22.	National Cancer Institute. NCI’s National Clinical Trials Network. Available from: https://www.cancer.gov/research/areas/clinical-trials/nctn.
23.	National Institute of Neurological Disorders and Stroke. NIH Stroke Trials Network. Available from: https://www.nihstrokenet.org/.
24.	National Institute of Allergy and Infectious Disease. The HIV Prevention Trials Network. Available from: https://www.hptn.org/.
25.	National Institutes of Health. Funding Opportunity Announcement RFA-NS-13-012 NINDS Stroke Trials Network - National Clinical Coordinating Center (U01). Available from: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-13-012.html.
26.	National Institutes of Health. Funding Opportunity Announcement RFA-NS-13-016 NINDS Stroke Trials Network - National Data Management Center (U01). Available from: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-13-016.html.
27.	National Institutes of Health. Funding Opportunity Announcement RFA-NS-13-011 NINDS Stroke Trials Network - Regional Coordinating Stroke Centers (U10). Available from: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-13-011.html.
28.	National Institutes of Health. NIH Single IRB Policy for Multi-site Research. Available from: https://grants.nih.gov/policy/humansubjects/single-irb-policy-multi-site-research.htm.

Chinese Journal of Evidence-Based Medicine

Lessons from COVID-19 clinical trials and the concept of national clinical trials network

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content